An observational study in Heart Failure, sponsored by Christian Hassager. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-14.
Sponsored by Christian Hassager · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.
Among the 242 studies in Heart Failure with a site in Denmark, this one is the 51st largest by planned enrollment of the 54 observational ones that give a count, is one of 13 that started in 2022, is one of 54 observational ones, and was the 182nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark, Finland, Norway and 1 more country
Ages 18–99
University of Aarhus · Sites in Denmark
Ages 18+
Novo Nordisk A/S · Sites in Denmark, United States, Argentina and 24 more countries
Ages 18+
Gødstrup Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
242 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 39 · Phase 3 43 · Phase 4 15
First in 1983; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 197 across the 187 interventional studies, 213 across the 54 observational. Of the 159 that completed or were terminated, 55 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 242 have an industry lead sponsor. The 10 most frequent:
Christian Hassager is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Christian Hassager has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT05063955Aarhus University HospitalMechanism of Sarcopenia in Heart Failure | 2026-12-31 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 242 studies in Heart Failure with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is an investigator-initiated, prospective cohort trial. The trial aims to evaluate ReDS Pro System V2.7 and ReDS ICU in patients with heart failure (HF).
The study is an investigator-initiated, prospective cohort trial. The trial aims to evaluate ReDS Pro System V2.7 and ReDS ICU in patients with heart failure (HF). The overall purposes are:
For the out-patient part, the patients will be recruited from the outpatient clinic at Rigshospitalet. The patient must be at least 18 years, have a history of chronic HF, and already monitored using CardioMEMS and must not fulfill any of the exclusion criteria.
For the ICU part, the patients will be recruited at the ICU department at the Heart Center at Rigshospitalet. The patient must be at least 18 years, intubated, and unconscious or sedated (Glasgow Coma Score \<8), and already monitored using Swan-Ganz and arterial catherization and must not fulfill any of the exclusion criteria.
ICU part:
Acute heart failure patients with Swan-Ganz catheter and an arterial catheter.
Outpatient part:
Chronic heart failure patients with CardioMEMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ICU part:
Out-patient part:
Exclusion Criteria:
ICU part:
Out-patient part:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acute heart failure patients with Swan-Ganz catheter and an arterial catheter.
Device: Remote Dielectric Sensing (ReDS)
Chronic heart failure patients with CardioMEMS.
Device: Remote Dielectric Sensing (ReDS)
Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
Correlation between ReDS ICU fluid parameters and Swan-Ganz measurements
Measurements on Swan-Ganz catheter (CVP, PAP, PCWP - all in mmHg) and the percentage of fluid in the lungs (%)
Time frame: Daily Swan-Ganz catheter and ReDS ICU measurements the first 72 hours after Swan-Ganz implantation
Correlation between ReDS v2.7 fluid parameters and CardioMEMS measurements
mPAP (mmHg), dPAP (mmHg) and the percentage of fluid in the lungs (%)
Time frame: 3 months
Changes in ReDS ICU fluid parameters following changes in Positive End Expiratory Pressure
The percentage of fluid in the lungs (%) and PEEP
Time frame: During the first 72 hours after Swan-Ganz implantation
Changes in ReDS ICU fluid parameters following raised leg test
The percentage of fluid in the lungs (%)
Time frame: During the first 72 hours after Swan-Ganz implantation
Changes in ReDS ICU fluid parameters following changes in body position
The percentage of fluid in the lungs (%)
Time frame: During the first 72 hours after Swan-Ganz implantation
Changes in ReDS ICU fluid parameters following changes administration of diuretics and inotropic/inodilators
The percentage of fluid in the lungs (%)
Time frame: During the first 72 hours after Swan-Ganz implantation
Correlation between ReDS v2.7 fluid parameters and body weight
The percentage of fluid in the lungs (%)
Time frame: 3 months
Correlation between ReDS v2.7 fluid parameters and dyspnea symptom evaluated by NYHA class.
The percentage of fluid in the lungs (%)
Time frame: 3 months
Plan to share: Yes — Data is planned to be available upon reasonable request via the Principal Investigator pending final, complete publication of the study.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Access and final IPD criteria is pending final, complete publication of the study.
Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA)
Started Jun 2022 (actual). Primary completion is estimated for Feb 2024, 19 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 19 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Christian Hassager